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Prolyl hydroxylases (PHDs) perceive intracellular oxygen tension and signal hypoxia-inducible factors (HIFs)
to induce hypoxia-adaptive processes such as angiogenesis. A paper from Chan and colleagues in the June
issue of Cancer Cell demonstrates that PHD2 inactivation in tumor cells accelerates tumor growth via HIF-
independent, NF-kB-mediated changes in tumor angiogenesis.Insufficient oxygenation (hypoxia) exists in
virtually all solid tumors; this is essentially
due to inadequate perfusion. Thus, prop-
erly balanced angiogenesis is clearly
missing in most solid tumors. The tran-
scription factor Hypoxia-inducible factor-
1 (HIF-1) facilitates hypoxic adaptation in
part through the induction of angiogenesis
(Semenza, 2007). HIF-1 consists of an
oxygen-sensitivea subunit andaconstitu-
tively stable b subunit. The HIF-1a subunit
is hydroxylated in an oxygen-dependent
manner by prolyl hydroxylases (PHDs),
which primes it for von Hippel-Lindau
(VHL)-mediated proteasomal degradation
(Ivan et al., 2001; Jaakkola et al., 2001;
Yu et al., 2001). Among three isoforms
(PHD1–3), genetic data argue that PHD2
is the most critical regulator of HIF-1a
stability. In turn, lowered activity of PHD2
under hypoxic conditions is one of the
most essential features ofHIF-1-mediated
induction of angiogenesis, through effec-
tors such as the vascular endothelial
growth factor (VEGF). A new study in
a recent issue of Cancer Cell by Chan
et al. (2009), however, demonstrates that
PHD2 also employs HIF-1/VEGF-inde-
pendent signaling to regulate tumor
angiogenesis, in an intriguing and novel
role for this hydroxylase.
Intracellular oxygen sensing is an evolu-
tionarily preserved process that allows
adaptation to hypoxia. PHDs are required
for oxygen sensing in both physiological
and pathological conditions, as has
been described in various animal model
studies. An important recent example
is the demonstration by Mazzone and
colleagues (2009) that PHD2 acts to
create a dysfunctional tumor vasculature
and to accelerate metastatic progression.
Their study employed wild-type tumor
cells placed in animals heterozygous for
a null allele of PHD2 and demonstratedthat a decreased level of PHD2 resulted
in increased HIF-dependent VEGF re-
ceptor-1 and VE-cadherin expression.
This decrease in PHD2 in the host animal
also resulted in decreased invasion and
intravasation of wild-type tumor cells
(Mazzone et al., 2009).
The study byChan et al. (2009) takes the
obverse approach to that of Mazzone and
colleagues, focusing on tumor cells with
shRNA-mediated decreases in PHD2
expression, now injected into wild-type
(immunocompromised) hosts. The loss of
PHD2 inmalignant cells accelerates tumor
growth and is associatedwith an induction
of angiogenesis and a recruitment of bone
marrow-derived cells. Interestingly, Maz-
zone and colleagues also document
an increase in the rate of primary tumor
growth in PHD2 hemizygous mice, al-
though in some of their models this
increase becomes nonsignificant when
tumors become very large (approx.
1 cm3). After this, the two studies diverge,
however, and it appears that the loss of
PHD2 in tumors in the Chan et al. (2009)
study increases vascular density,whereas
the hemizygosity of host animals for PHD2
in theMazzone et al. (2009) study results in
no significant change in vessel density. A
further divergence is in the HIF depen-
dency of the effects documented in the
PHD2 hemizygous mice; in contrast, the
loss of PHD2 in tumor cells is shown by
Chan and colleagues (2009) to effect
vascular changes in a HIF-independent
fashion.
Cummins et al. (2006) have reported
that PHD1 or PHD2 can act on IkB kinase
b, a regulator of the inflammatory tran-
scription factor NF-kB, indicating that
PHD2 may have a HIF-1a-independent
role in tissue and inflammatory cell mobi-
lization. Indeed, Chan et al. (2009) demon-
strate that PHD2-mediated regulation ofDevelopmental Cetumor vascularization and tumor growth
are directly related to NF-kB signaling.
They describe how PHD2 knockdown
increases the expression of two NF-kB
target angiogenic factors, interleukin-8
and angiogenin, that can mediate angio-
genesis and vasculogenesis.
This angiogenic activation via PHD2
knockdown occurs even in tumor cells
with a HIF-1a or HIF-2a knockdown in
place. It is possible that tumor cells may
use these two pathways in a spatially
complementary way; since the tumor
microenvironment displays a heteroge-
neous mixture of hypoxic and nonhypoxic
regions, HIF-independent, NF-kB-medi-
ated signaling may be part of a PHD2-
driven process in nonhypoxic regions
(Naugler and Karin, 2008). In this regard,
it is notable that Chan and colleagues
(2009) found no strong correlation of
PHD2 expression with HIF levels in a
comprehensive analysis of human cancer
cell lines.
Given that little is known about non-HIF
substrates for PHDs and, further, given
Chan and colleagues’ additional (and
surprising) finding that the hydroxylase
function of PHD2 may not be required
for angiogenic suppression, it will be of
great interest to delineate the molecular
mechanisms underpinning the nonenzy-
matic functions of PHDs. It should also
be interesting to determine whether this
HIF-independent angiogenic regulation
by PHD2 is associated with normal tissue
function and physiology.
Interestingly, these two studies, from
the Giaccia group at Stanford and the
Carmeliet group at Leuven, come to
somewhat different conclusions about
the role of PHD2 in tumorigenesis.
Although both show that loss of PHD2
can increase tumor growth, the overall
effects on the vasculature that theyll 16, June 16, 2009 ª2009 Elsevier Inc. 781
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Previewsdocument in their models differ signifi-
cantly. This is actually not surprising given
that the former group addresses the
factor from the perspective of the malig-
nant cell and the latter group from the
standpoint of the host response. An anal-
ysis of the role of PHD2, coupling manip-
ulations in both malignant and stromal
cells, should aid greatly in resolving the
issues these two studies raise regarding
the role of PHD2 in tumorigenic progres-
sion, invasion, and metastasis.782 Developmental Cell 16, June 16, 2009 ªREFERENCES
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